BRCA1 and BRCA2 mutations in a population-based study of male breast cancer.

Abstract:

BACKGROUND:The contribution of BRCA1 and BRCA2 to the incidence of male breast cancer (MBC) in the United Kingdom is not known, and the importance of these genes in the increased risk of female breast cancer associated with a family history of breast cancer in a male first-degree relative is unclear. METHODS:We have carried out a population-based study of 94 MBC cases collected in the UK. We screened genomic DNA for mutations in BRCA1 and BRCA2 and used family history data from these cases to calculate the risk of breast cancer to female relatives of MBC cases. We also estimated the contribution of BRCA1 and BRCA2 to this risk. RESULTS:Nineteen cases (20%) reported a first-degree relative with breast cancer, of whom seven also had an affected second-degree relative. The breast cancer risk in female first-degree relatives was 2.4 times (95% confidence interval [CI] = 1.4-4.0) the risk in the general population. No BRCA1 mutation carriers were identified and five cases were found to carry a mutation in BRCA2. Allowing for a mutation detection sensitivity frequency of 70%, the carrier frequency for BRCA2 mutations was 8% (95% CI = 3-19). All the mutation carriers had a family history of breast, ovarian, prostate or pancreatic cancer. However, BRCA2 accounted for only 15% of the excess familial risk of breast cancer in female first-degree relatives. CONCLUSION:These data suggest that other genes that confer an increased risk for both female and male breast cancer have yet to be found.

journal_name

Breast Cancer Res

authors

Basham VM,Lipscombe JM,Ward JM,Gayther SA,Ponder BA,Easton DF,Pharoah PD

doi

10.1186/bcr419

keywords:

subject

Has Abstract

pub_date

2002-01-01 00:00:00

pages

R2

issue

1

eissn

1465-5411

issn

1465-542X

journal_volume

4

pub_type

杂志文章
  • Adolescent diet and risk of breast cancer.

    abstract:BACKGROUND:Early life exposures, including diet, have been implicated in the etiology of breast cancer. METHODS:A nested case-control study was conducted among participants in the Nurses' Health Study who completed a 24-item questionnaire about diet during high school. There were 843 eligible cases diagnosed between o...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr583

    authors: Frazier AL,Ryan CT,Rockett H,Willett WC,Colditz GA

    更新日期:2003-01-01 00:00:00

  • The CD44+/CD24- phenotype is enriched in basal-like breast tumors.

    abstract:INTRODUCTION:Human breast tumors are heterogeneous and consist of phenotypically diverse cells. Breast cancer cells with a CD44+/CD24- phenotype have been suggested to have tumor-initiating properties with stem cell-like and invasive features, although it is unclear whether their presence within a tumor has clinical im...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2108

    authors: Honeth G,Bendahl PO,Ringnér M,Saal LH,Gruvberger-Saal SK,Lövgren K,Grabau D,Fernö M,Borg A,Hegardt C

    更新日期:2008-01-01 00:00:00

  • Circulating levels of 25-hydroxyvitamin D and risk of breast cancer: a nested case-control study.

    abstract:INTRODUCTION:Experimental evidence suggests a protective role for circulating 25-hydroxyvitamin D (25(OH)D) in breast cancer development, but the results of epidemiological studies have been inconsistent. METHODS:We conducted a case-control study nested within two prospective cohorts, the New York University Women's H...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3390

    authors: Scarmo S,Afanasyeva Y,Lenner P,Koenig KL,Horst RL,Clendenen TV,Arslan AA,Chen Y,Hallmans G,Lundin E,Rinaldi S,Toniolo P,Shore RE,Zeleniuch-Jacquotte A

    更新日期:2013-02-26 00:00:00

  • Targeted therapies in breast cancer: are heart and vessels also being targeted?

    abstract::The concept of 'targeted' therapies implies that such drugs only act on cells that specifically express the particular target, therefore giving rise to a low incidence of side effects. However, targeted therapies currently approved for the treatment of breast cancer have demonstrated a relatively high incidence of car...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr3142

    authors: Criscitiello C,Metzger-Filho O,Saini KS,de Castro G Jr,Diaz M,La Gerche A,de Azambuja E,Piccart-Gebhart MJ

    更新日期:2012-06-19 00:00:00

  • High expression of focal adhesion kinase (p125FAK) in node-negative breast cancer is related to overexpression of HER-2/neu and activated Akt kinase but does not predict outcome.

    abstract:INTRODUCTION:Focal adhesion kinase (FAK) regulates multiple cellular processes including growth, differentiation, adhesion, motility and apoptosis. In breast carcinoma, FAK overexpression has been linked to cancer progression but the prognostic relevance remains unknown. In particular, with regard to lymph node-negativ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr977

    authors: Schmitz KJ,Grabellus F,Callies R,Otterbach F,Wohlschlaeger J,Levkau B,Kimmig R,Schmid KW,Baba HA

    更新日期:2005-01-01 00:00:00

  • The clinical and functional significance of c-Met in breast cancer: a review.

    abstract::c-Met is a receptor tyrosine kinase that upon binding of its ligand, hepatocyte growth factor (HGF), activates downstream pathways with diverse cellular functions that are important in organ development and cancer progression. Anomalous c-Met signalling has been described in a variety of cancer types, and the receptor...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/s13058-015-0547-6

    authors: Ho-Yen CM,Jones JL,Kermorgant S

    更新日期:2015-04-08 00:00:00

  • Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women.

    abstract:BACKGROUND:Most BRCA1 or BRCA2 mutation carriers have inherited a single (heterozygous) mutation. Transheterozygotes (TH) who have inherited deleterious mutations in both BRCA1 and BRCA2 are rare, and the consequences of transheterozygosity are poorly understood. METHODS:From 32,295 female BRCA1/2 mutation carriers, w...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,多中心研究

    doi:10.1186/s13058-016-0768-3

    authors: Rebbeck TR,Friebel TM,Mitra N,Wan F,Chen S,Andrulis IL,Apostolou P,Arnold N,Arun BK,Barrowdale D,Benitez J,Berger R,Berthet P,Borg A,Buys SS,Caldes T,Carter J,Chiquette J,Claes KB,Couch FJ,Cybulski C,Daly MB,d

    更新日期:2016-11-11 00:00:00

  • Pre-analytic variables and phospho-specific antibodies: the Achilles heel of immunohistochemistry.

    abstract::Immunohistochemistry is the most common method for companion diagnostic testing in breast cancer. The readings for estrogen receptor, progesterone receptor, and Her2 directly affect prescription of critical therapies. However, immunohistochemistry is highly sensitive to innumerable pre-analytic variables that result i...

    journal_title:Breast cancer research : BCR

    pub_type: 社论

    doi:10.1186/bcr2782

    authors: Siddiqui S,Rimm DL

    更新日期:2010-01-01 00:00:00

  • The pathology of familial breast cancer: Morphological aspects.

    abstract::A small proportion of breast cancers are due to a heritable predisposition. Recently, two predisposition genes, BRCA1 and BRCA2, have been identified and cloned. The morphological features of tumours from patients harbouring mutations in the BRCA1 and BRCA2 genes differ from each other and from sporadic breast cancers...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr10

    authors: Lakhani SR

    更新日期:1999-01-01 00:00:00

  • Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation of nuclear factor-kappaB and c-Jun N-terminal kinase pathways.

    abstract:INTRODUCTION:Metastasis is the main cause of breast cancer morbidity and mortality. Processes that allow for tumor cell migration and invasion are important therapeutic targets. Here we demonstrate that receptor-interacting protein kinase 2 (RIP2), a kinase known to be involved in inflammatory processes, also has novel...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3629

    authors: Singel SM,Batten K,Cornelius C,Jia G,Fasciani G,Barron SL,Wright WE,Shay JW

    更新日期:2014-03-19 00:00:00

  • Measuring proliferation in breast cancer: practicalities and applications.

    abstract::Various methods are available for the measurement of proliferation rates in tumours, including mitotic counts, estimation of the fraction of cells in S-phase of the cell cycle and immunohistochemistry of proliferation-associated antigens. The evidence, advantages and disadvantages for each of these methods along with ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr1618

    authors: Beresford MJ,Wilson GD,Makris A

    更新日期:2006-01-01 00:00:00

  • Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts.

    abstract:INTRODUCTION:Rapamycin, an inhibitor of the serine/threonine kinase target of rapamycin, induces G1 arrest and/or apoptosis. Although rapamycin and its analogues are attractive candidates for cancer therapy, their sensitivities with respect to growth inhibition differ markedly among various cancer cells. Using human br...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1344

    authors: Kasukabe T,Okabe-Kado J,Kato N,Sassa T,Honma Y

    更新日期:2005-01-01 00:00:00

  • Analysis of EpCAM positive cells isolated from sentinel lymph nodes of breast cancer patients identifies subpopulations of cells with distinct transcription profiles.

    abstract:INTRODUCTION:The presence of tumor cells in the axillary lymph nodes is the most important prognostic factor in early stage breast cancer. However, the optimal method for sentinel lymph node (SLN) examination is still sought and currently many different protocols are employed. To examine two approaches for tumor cell d...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2922

    authors: Tveito S,Andersen K,Kåresen R,Fodstad Ø

    更新日期:2011-08-04 00:00:00

  • Not all false positive diagnoses are equal: On the prognostic implications of false-positive diagnoses made in breast MRI versus in mammography / digital tomosynthesis screening.

    abstract:BACKGROUND:Breast magnetic resonance imaging (MRI) has been reported to frequently result in false-positive diagnoses, limiting its positive predictive value (PPV). However, for PPV calculation, all nonmalignant tissue changes are equally considered false-positive, although the respective prognostic importance, and thu...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-018-0937-7

    authors: Kuhl CK,Keulers A,Strobel K,Schneider H,Gaisa N,Schrading S

    更新日期:2018-02-09 00:00:00

  • Vaccinia virus GLV-1h153 is a novel agent for detection and effective local control of positive surgical margins for breast cancer.

    abstract:INTRODUCTION:Surgery is currently the definitive treatment for early-stage breast cancer. However, the rate of positive surgical margins remains unacceptably high. The human sodium iodide symporter (hNIS) is a naturally occurring protein in human thyroid tissue, which enables cells to concentrate radionuclides. The hNI...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3404

    authors: Gholami S,Chen CH,Belin LJ,Lou E,Fujisawa S,Antonacci C,Carew A,Chen NG,De Brot M,Zanzonico PB,Szalay AA,Fong Y

    更新日期:2013-03-18 00:00:00

  • Upregulation of EGFR signaling is correlated with tumor stroma remodeling and tumor recurrence in FGFR1-driven breast cancer.

    abstract:INTRODUCTION:Despite advances in early detection and adjuvant targeted therapies, breast cancer is still the second most common cause of cancer mortality among women. Tumor recurrence is one of the major contributors to breast cancer mortality. However, the mechanisms underlying this process are not completely understo...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-015-0649-1

    authors: Holdman XB,Welte T,Rajapakshe K,Pond A,Coarfa C,Mo Q,Huang S,Hilsenbeck SG,Edwards DP,Zhang X,Rosen JM

    更新日期:2015-11-18 00:00:00

  • Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.

    abstract:INTRODUCTION:Reliable predictive and prognostic markers for routine diagnostic purposes are needed for breast cancer patients treated with neoadjuvant chemotherapy. We evaluated protein biomarkers in a cohort of 116 participants of the GeparDuo study on anthracycline/taxane-based neoadjuvant chemotherapy for operable b...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1186/bcr2363

    authors: Darb-Esfahani S,Loibl S,Müller BM,Roller M,Denkert C,Komor M,Schlüns K,Blohmer JU,Budczies J,Gerber B,Noske A,du Bois A,Weichert W,Jackisch C,Dietel M,Richter K,Kaufmann M,von Minckwitz G

    更新日期:2009-01-01 00:00:00

  • Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors.

    abstract:INTRODUCTION:Aromatase inhibitor-associated arthralgia (AIAA) is a common and often debilitating symptom in breast cancer survivors. Since joint symptoms have been related to estrogen deprivation through the menopausal transition, we hypothesized that genetic polymorphisms in CYP19A1, the final enzyme in estrogen synth...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2813

    authors: Mao JJ,Su HI,Feng R,Donelson ML,Aplenc R,Rebbeck TR,Stanczyk F,DeMichele A

    更新日期:2011-01-20 00:00:00

  • FAK activates AKT-mTOR signaling to promote the growth and progression of MMTV-Wnt1-driven basal-like mammary tumors.

    abstract:BACKGROUND:Breast cancer is a heterogeneous disease. Hence, stratification of patients based on the subtype of breast cancer is key to its successful treatment. Among all the breast cancer subtypes, basal-like breast cancer is the most aggressive subtype with limited treatment options. Interestingly, we found focal adh...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-020-01298-3

    authors: Paul R,Luo M,Mo X,Lu J,Yeo SK,Guan JL

    更新日期:2020-06-03 00:00:00

  • MiR-7 reduces the BCSC subset by inhibiting XIST to modulate the miR-92b/Slug/ESA axis and inhibit tumor growth.

    abstract:BACKGROUND:Breast cancer stem cells (BCSCs) are typically seed cells of breast tumor that initiate and maintain tumor growth. MiR-7, as a cancer inhibitor, decreases the BCSC subset and inhibits tumor progression through mechanisms that remain unknown. METHODS:We examined miR-7 expression in breast cancer and develope...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-020-01264-z

    authors: Li M,Pan M,You C,Zhao F,Wu D,Guo M,Xu H,Shi F,Zheng D,Dou J

    更新日期:2020-03-06 00:00:00

  • Polymorphic repeat in AIB1 does not alter breast cancer risk.

    abstract::STATEMENT OF FINDINGS: We assessed the association between a glutamine repeat polymorphism in AIB1 and breast cancer risk in a case-control study (464 cases, 624 controls) nested within the Nurses' Health Study cohort. We observed no association between AIB1 genotype and breast cancer incidence, or specific tumor char...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr82

    authors: Haiman CA,Hankinson SE,Spiegelman D,Colditz GA,Willett WC,Speizer FE,Brown M,Hunter DJ

    更新日期:2000-01-01 00:00:00

  • Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study.

    abstract:INTRODUCTION:Before any new methodology can be introduced into the routine diagnostic setting it must be technically validated against the established standards. To this end, a ring study involving five international pathology laboratories was initiated to validate chromogenic in situ hybridisation (CISH) against fluor...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,多中心研究

    doi:10.1186/bcr1776

    authors: van de Vijver M,Bilous M,Hanna W,Hofmann M,Kristel P,Penault-Llorca F,Rüschoff J

    更新日期:2007-01-01 00:00:00

  • Direct repression of MYB by ZEB1 suppresses proliferation and epithelial gene expression during epithelial-to-mesenchymal transition of breast cancer cells.

    abstract:INTRODUCTION:Epithelial-to-mesenchymal transition (EMT) promotes cell migration and is important in metastasis. Cellular proliferation is often downregulated during EMT, and the reverse transition (MET) in metastases appears to be required for restoration of proliferation in secondary tumors. We studied the interplay b...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3580

    authors: Hugo HJ,Pereira L,Suryadinata R,Drabsch Y,Gonda TJ,Gunasinghe NP,Pinto C,Soo ET,van Denderen BJ,Hill P,Ramsay RG,Sarcevic B,Newgreen DF,Thompson EW

    更新日期:2013-11-27 00:00:00

  • The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis.

    abstract:INTRODUCTION:Matrix metalloproteinase (MMP)-2 is very active at degrading extracellular matrix. It is under the influence of an activator, membrane type 1 MMP (MMP-14), and the tissue inhibitor of metalloproteases (TIMP)-2. We hypothesized that the individual expression of these three markers or their balance may help ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1503

    authors: Têtu B,Brisson J,Wang CS,Lapointe H,Beaudry G,Blanchette C,Trudel D

    更新日期:2006-01-01 00:00:00

  • Breast tumors: of mice and women.

    abstract::For the past 20 years the mouse has served as a workhorse for studying the molecular underpinnings of human breast cancer. While some genetically engineered mouse mammary tumor models do not accurately recapitulate human disease (that is, the MMTV-Neu model and HER2-overexpressing human cancers), additional tumor mode...

    journal_title:Breast cancer research : BCR

    pub_type: 评论,社论

    doi:10.1186/bcr2569

    authors: McDermott SP,Wicha MS

    更新日期:2010-01-01 00:00:00

  • Genomic signature of parity in the breast of premenopausal women.

    abstract:BACKGROUND:Full-term pregnancy (FTP) at an early age confers long-term protection against breast cancer. Previously, we reported that a FTP imprints a specific gene expression profile in the breast of postmenopausal women. Herein, we evaluated gene expression changes induced by parity in the breast of premenopausal wom...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-019-1128-x

    authors: Santucci-Pereira J,Zeleniuch-Jacquotte A,Afanasyeva Y,Zhong H,Slifker M,Peri S,Ross EA,López de Cicco R,Zhai Y,Nguyen T,Sheriff F,Russo IH,Su Y,Arslan AA,Bordas P,Lenner P,Åhman J,Landström Eriksson AS,Johansson R,H

    更新日期:2019-03-28 00:00:00

  • Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers.

    abstract:INTRODUCTION:Human epidermal growth factor receptor-2 (HER2) gene amplification (HER2+) drives tumor cell growth and survival in ~25% of breast cancers. HER2 signaling activates the type I phosphoinositide 3-kinase (PI3K), upon which these tumors rely. Consequently, inhibitors of HER2 and type I PI3K block growth and i...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-015-0656-2

    authors: Young CD,Arteaga CL,Cook RS

    更新日期:2015-12-04 00:00:00

  • Digoxin treatment is associated with an increased incidence of breast cancer: a population-based case-control study.

    abstract:INTRODUCTION:Laboratory and epidemiologic studies have suggested a modifying effect of cardiac glycosides (for example, digoxin and digitoxin) on cancer risk. We explored the association between digoxin treatment and invasive breast cancer incidence among postmenopausal Danish women. METHODS:We used Danish registries ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2205

    authors: Ahern TP,Lash TL,Sørensen HT,Pedersen L

    更新日期:2008-01-01 00:00:00

  • A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.

    abstract:INTRODUCTION:There is an unmet clinical need for biomarkers to identify breast cancer patients at an increased risk of developing brain metastases. The objective is to identify gene signatures and biological pathways associated with human epidermal growth factor receptor 2-positive (HER2+) brain metastasis. METHODS:We...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3625

    authors: McMullin RP,Wittner BS,Yang C,Denton-Schneider BR,Hicks D,Singavarapu R,Moulis S,Lee J,Akbari MR,Narod SA,Aldape KD,Steeg PS,Ramaswamy S,Sgroi DC

    更新日期:2014-03-14 00:00:00

  • 17-allyamino-17-demethoxygeldanamycin treatment results in a magnetic resonance spectroscopy-detectable elevation in choline-containing metabolites associated with increased expression of choline transporter SLC44A1 and phospholipase A2.

    abstract:INTRODUCTION:17-allyamino-17-demethoxygeldanamycin (17-AAG), a small molecule inhibitor of Hsp90, is currently in clinical trials in breast cancer. However, 17-AAG treatment often results in inhibition of tumor growth rather than shrinkage, making detection of response a challenge. Magnetic resonance spectroscopy (MRS)...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2729

    authors: Brandes AH,Ward CS,Ronen SM

    更新日期:2010-01-01 00:00:00